Monte Rosa Therapeutics, Inc. (GLUE) Current Ratio
- Current ratio · latest quarter: Value 10.58×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.58× | Current assets / current liabilities. $631.41M ÷ $59.66M ≈ 10.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 631.41M USD | Assets, Current |
| Current obligations | 59.66M USD | Liabilities, Current |
| Cash and equivalents | 90.10M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 7.15M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $631.41M | $59.66M | $90.10M | (m) | (m) | (m) | $7.15M | (m) | 10.58× |
| 2026-03-31 | $677.55M | $71.04M | $159.86M | (m) | (m) | (m) | $7.90M | (m) | 9.54× |
| 2025-12-31 | $393.19M | $64.21M | $129.88M | (m) | (m) | (m) | $3.55M | (m) | 6.12× |
| 2025-09-30 | $401.82M | $61.44M | $208.34M | (m) | (m) | (m) | $14.51M | (m) | 6.54× |
| 2025-06-30 | $299.46M | $41.85M | $69.43M | (m) | (m) | (m) | $5.58M | (m) | 7.16× |
| 2025-03-31 | $332.28M | $59.22M | $78.53M | (m) | (m) | (m) | $6.49M | (m) | 5.61× |
| 2024-12-31 | $377.44M | $156.95M | $224.25M | (m) | (m) | (m) | $17.21M | (m) | 2.40× |
| 2024-09-30 | $251.21M | $41.64M | $125.58M | (m) | (m) | (m) | $3.98M | (m) | 6.03× |
| 2024-06-30 | $277.90M | $42.35M | $108.85M | (m) | $9.00M | (m) | $6.47M | (m) | 6.56× |
| 2024-03-31 | $199.04M | $41.29M | $99.75M | (m) | (m) | (m) | $6.83M | (m) | 4.82× |
| 2023-12-31 | $236.21M | $46.59M | $128.10M | (m) | (m) | (m) | $11.15M | (m) | 5.07× |
| 2023-09-30 | $182.91M | $22.61M | $59.05M | (m) | (m) | (m) | $5.50M | (m) | 8.09× |
| 2023-06-30 | $208.10M | $19.09M | $47.03M | (m) | (m) | (m) | $5.31M | (m) | 10.90× |
| 2023-03-31 | $240.56M | $20.52M | $51.85M | (m) | (m) | (m) | $7.38M | (m) | 11.73× |
| 2022-12-31 | $275.89M | $25.57M | $54.91M | (m) | (m) | (m) | $7.86M | (m) | 10.79× |
| 2022-09-30 | $295.24M | $21.79M | $112.39M | (m) | (m) | (m) | $9.75M | (m) | 13.55× |
| 2022-06-30 | $297.05M | $14.77M | $103.66M | (m) | (m) | (m) | $4.29M | (m) | 20.11× |
| 2022-03-31 | $320.37M | $12.49M | $138.31M | (m) | (m) | (m) | $4.51M | (m) | 25.65× |
| 2021-12-31 | $348.67M | $16.64M | $346.07M | (m) | (m) | (m) | $6.56M | (m) | 20.96× |
| 2021-09-30 | $370.52M | $12.74M | $367.03M | (m) | (m) | (m) | $3.53M | (m) | 29.08× |
| 2021-06-30 | $358.29M | $10.79M | $357.06M | (m) | (m) | (m) | $7.46M | (m) | 33.20× |
| 2020-12-31 | $43.59M | $29.27M | $41.70M | (m) | (m) | (m) | $7.07M | (m) | 1.49× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |